Company Overview and News

2
Banks Q2 Earnings Slated on Jul 20: STT, STI, RF, CFG

14h zacks
After an impressive first-quarter performance, driven by significant volatility, banks are losing momentum on the flattening of the yield curve. Therefore, net interest margin (NIM), which is the backbone for banks’ top-line growth, is expected to have remained subdued in the second quarter. Nonetheless, given the benefits of rising interest rates, along with a moderate improvement in lending — particularly commercial and industrial (C&I), and consumer loans, banks’ net interest income (NII) is expected to have received some boost during the quarter.
STT RF.PRB STI.WS.B RF.PRA STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG RF CFG CFIN STI CIWV STI-A STI.PRE

2
Can TD Ameritrade (AMTD) Sustain Earnings Beat Streak in Q3?

15h zacks
TD Ameritrade Holding Corporation (AMTD - Free Report) is scheduled to report third-quarter fiscal 2018 results, after the market closes on Jul 23. The company is expected to report year-over-year growth in revenues and earnings.
STT STI.WS.B STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG LMHA LMHB STI STI-A AMTD STI.PRE LM

46
BNY Mellon (BK) Q2 Earnings In Line With Estimates, Costs Up

15h zacks
The Bank of New York Mellon Corporation’s (BK - Free Report) second-quarter 2018 earnings per share of $1.03 was in-line with the Zacks Consensus Estimate. The figure reflects an improvement of 17% from the prior-year quarter. Results benefited from an improvement in revenues along with provision benefits. Also, assets under management (AUM) reflected growth. However, rise in expenses acted as a headwind.
STT BAC STI.WS.B STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG BAC STI BK STI-A STI.PRE

1
Canadian ETFs: Capturing Investors' Mind Space

19h blogs.cfainstitute.org
Ever since Toronto 35 Index Participation Units (TIPs 35) went up for sale in 1990, Canada has played an outsized role in the development and evolution of exchange-traded funds (ETFs).
STT STT.PRC STT.PRE STT.PRD STT.PRG BB TD

1
Index Funds Are Going to Be Just Fine - Bloomberg

2018-07-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
STT BLK STT.PRC STT.PRE STT.PRD STT.PRG

3
7 Cybersecurity Funds for Growth Investors | InvestorPlace

2018-07-18 investorplace
Over the past several years, cybersecurity has emerged as one of the hottest themes in the broader technology sector. Data suggest it could also be one of the most durable technology investment themes over the long-term.
STT STT.PRC STT.PRE XKFS STT.PRD STT.PRG DTEC CSCO NYTAB AIQ CIBR

1
WisdomTree Looks Clearly Overvalued

2018-07-18 seekingalpha
Its growth history has stopped a couple of years ago and there aren’t much prospects of things turning around soon.
STT WETF BLK SPGI STT.PRC DXJ STT.PRE STT.PRD STT.PRG IVZ

1
XLF: Has Diversity And My Favorite Bank

2018-07-18 seekingalpha
The fund has a reasonable valuation and a growing yield, two metrics that look good when the market is volatile.
STT STT.PRC STT.PRE STT.PRD STT.PRG

15
US Financial 15 Split Corp. Preferred Dividend Declared

2018-07-18 globenewswire
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- US Financial 15 Split Corp ("US Financial 15") declares its monthly distribution of $0.03938 for each Preferred share, or 5.25% annually based on the previous month end net asset value. Distributions are payable August 10, 2018 to shareholders on record as at July 31, 2018.
GS.PRB MS.PRE GS.PRA RF MS.PRF MS.PRG MS.PRA FITBI GLSSP STI-A MS STT JBK STI.WS.B STI.WS.A TFG GS.PRJ GS.PRI STI 7018 MS.PRI GS.PRD MS.PRK GS.PRC FITB GS.PRN GS.PRK WFCNP RF.PRB RF.PRA STT.PRC STT.PRE STT.PRD STT.PRG WFC.PRL WFC.PRJ WFC.PRT GS WFC.PRR WFC.PRQ WFC.PRP CME WFC.PRO WFC.PRN STI.PRE WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS GSC GS.PRICL GSJ GJS

17
Can Interest Income Aid Capital One's (COF) Earnings in Q2?

2018-07-18 zacks
Capital One (COF - Free Report) is slated to release second-quarter 2018 results tomorrow, after market close. The company will likely witness an increase in total net interest income (NII) on a year-over-year basis. Driven by an improving economy, purchase volume growth and credit card loans (part of broader consumer loan portfolio) continued to increase during the second quarter. This, along with higher interest rates, are likely to support Capital One’s credit card NII.
STT STI.WS.B GEC GE STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG KEY STI STI-A GNE STI.PRE

18
Will Loan Growth, Fee Income Aid SunTrust (STI) Q2 Earnings?

2018-07-18 zacks
SunTrust Banks (STI - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the opening bell. Its revenues and earnings are projected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from rise in net interest income as well as lower expenses and provisions. However, a decline in non-interest income was the undermining factor.
STT STI.WS.B GEC GE STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG KEY STI ETFC STI-A GNE STI.PRE

16
Will Loan Growth Benefit Regions Financial (RF) Q2 Earnings?

2018-07-18 zacks
Regions Financial (RF - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the opening bell. The bank’s results are estimated to reflect year-over-year rise in both revenues and earnings. Also, the company has a decent earnings surprise history. It topped earnings in three of the trailing four quarters, with an average positive earnings surprise of 5.2%. This Birmingham, AL-based company’s first-quarter 2018 earnings outpaced the Zacks Consensus Estimate and compared favorably with the prior-year quarter’s earnings as well.
STT RF.PRB STI.WS.B GEC RF.PRA GE STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG RF STI STI-A GNE STI.PRE CFR

3
Can Higher Rates Aid State Street's (STT) Earnings in Q2?

2018-07-18 zacks
State Street (STT - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the market opens. Its earnings and revenues are expected to grow year over year. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results were aided by an increase in revenues, partly offset by higher expenses. Moreover, State Street boasts an impressive earnings surprise history.
STT HD STI.WS.B STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG KEY STI ETFC STI-A STI.PRE

1
Transcript: DFA's Dave Butler - The Big Picture

2018-07-17 ritholtz
You can stream/download the full conversation, including the podcast extras on iTunes, Bloomberg, Overcast, and Stitcher. Our earlier podcasts can all be found on iTunes, Stitcher, Overcast, and Bloomberg.
STT STT.PRC STT.PRE STT.PRD STT.PRG

6
Will Rising Rates Support Fifth Third's (FITB) Q2 Earnings?

2018-07-17 zacks
Fifth Third Bancorp (FITB - Free Report) is scheduled to report second-quarter 2018 results on Jul 19, before the opening bell. The bank’s results are anticipated to reflect year-over-year growth in revenues and earnings. Also, the company has a decent earnings surprise history. It topped earnings in three of the trailing four quarters, with an average positive earnings surprise of 9.7%. In the last reported quarter, the bank’s earnings had surpassed the Zacks Consensus Estimate.
STT STI.WS.B STI.WS.A STT.PRC STT.PRE STT.PRD STT.PRG FITBI STI STI-A FITB STI.PRE CFR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...